Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Suzhou Zelgen Biopharmaceuticals Co Forward PE Ratio Related Terms
Suzhou Zelgen Biopharmaceuticals Co Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Zelgen Biopharmaceuticals Co Forward PE Ratio Chart
Suzhou Zelgen Biopharmaceuticals Co Annual Data
Trend
2024-12
2025-12
Forward PE Ratio
147.34
133.24
Suzhou Zelgen Biopharmaceuticals Co Quarterly Data
2024-12
2025-03
2025-09
2025-12
2026-03
2026-06
Forward PE Ratio
147.34
203.79
143.34
133.24
93.67
52.35
SHSE:688266 vs VRTX, REGN, MRNA: Forward PE Ratio Comparison
For the Biotechnology subindustry, Suzhou Zelgen Biopharmaceuticals Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Zelgen Biopharmaceuticals Co Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Suzhou Zelgen Biopharmaceuticals Co's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Suzhou Zelgen Biopharmaceuticals Co's Forward PE Ratio falls into.
Suzhou Zelgen Biopharmaceuticals Co Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) has a Forward PE Ratio of 68.72 as of Sep. 05, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors. According to the industry distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #322 out of 385 companies in the Biotechnology industry, placing it in the top 83.6%.
Is Suzhou Zelgen Biopharmaceuticals Co's Forward PE Ratio too high?
Suzhou Zelgen Biopharmaceuticals Co's current Forward PE Ratio is 68.72. The Biotechnology industry median Forward PE Ratio is 20.82. Suzhou Zelgen Biopharmaceuticals Co's value of 68.72 is 230.1% above this industry median. Based on the distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #322 out of 385 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Suzhou Zelgen Biopharmaceuticals Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Zelgen Biopharmaceuticals Co's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #322 out of 385 companies for Forward PE Ratio. This places Suzhou Zelgen Biopharmaceuticals Co in the lower half of its industry. The industry median Forward PE Ratio is 20.82. Suzhou Zelgen Biopharmaceuticals Co's value of 68.72 is 230.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 20.82, based on 385 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzhou Zelgen Biopharmaceuticals Co's current Forward PE Ratio of 68.72 is 230.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 20.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Zelgen Biopharmaceuticals Co's current Forward PE Ratio is 68.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Zelgen Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥222.27, compared to a current price of ¥117.99 — trading 46.9% below its estimated fair value. The current Forward PE Ratio is 68.72 and 230.1% above the Biotechnology industry median of 20.82. Suzhou Zelgen Biopharmaceuticals Co's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266), the current Forward PE Ratio is 68.72 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Overvalued in 2026?
Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥117.99 is trading 46.9% below its estimated GF Value™ of ¥222.27.
GuruFocus considers Suzhou Zelgen Biopharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for SHSE:688266:
Forward PE Ratio: 68.72
GF Value™: ¥222.27 vs. price of ¥117.99 (46.9% below fair value)
Industry Position: 230.1% above the Biotechnology median (#322 of 385)
No single metric tells the full story. See the SHSE:688266 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
70GF Score
Get the complete analysis for SHSE:688266
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688266 has been successfully added to your 
